Apis Capital Advisors’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Apis Capital Advisors’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.82M	Buy	34,000 +500	+1%	+$29.1K	2.85%	11
2019 Q2	$2M	Sell	33,500 -2,500	-7%	-$157K	2.99%	8
2019 Q1	$2.24M	Sell	36,000 -4,000	-10%	-$265K	2.71%	8
2018 Q4	$2.42M	Buy	+40,000	New	+$2.39M	3.25%	12
2015 Q3	$3.73M	Buy	85,770 +9,806	+13%	+$529K	5.17%	6
2015 Q2	$3.92M	Sell	75,964 -6,836	-8%	-$291K	4.4%	9
2015 Q1	$2.47M	Buy	82,800 +24,600	+42%	+$964K	3.37%	11
2014 Q4	$2.25M	Buy	+58,200	New	+$2.22M	2.5%	14

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Apis Capital Advisors's BSTC Position: Q3 2019 in Review

Apis Capital Advisors increased its BioSpecifics Technologies Corp. (BSTC) stake by 1.5% in Q3 2019, buying an estimated $29.1K and bringing the position to 34,000 shares worth $1.82M. The position accounts for 2.85% of the portfolio, ranked #11.

Apis Capital Advisors first reported a position in BSTC in Q4 2014 and has held it in 8 quarters since. The position peaked at $3.92M in Q2 2015. 114 funds tracked by Wall St. Rank hold BSTC as of Q3 2019.

Apis Capital Advisors held 34,000 shares of BioSpecifics Technologies Corp. worth $1.82M as of Q3 2019.
Apis Capital Advisors bought 500 BioSpecifics Technologies Corp. shares in Q3 2019, an estimated $29.1K.
BioSpecifics Technologies Corp. made up 2.85% of Apis Capital Advisors's portfolio in Q3 2019, its #11 holding.
Apis Capital Advisors first reported a position in BioSpecifics Technologies Corp. in Q4 2014 and has held it in 8 quarters since.
Apis Capital Advisors's BioSpecifics Technologies Corp. position peaked at $3.92M in Q2 2015.
114 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2019.

Based on Apis Capital Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.